United Immunity Acquires Macrophage Assets from Carisma Therapeutics for the Treatment of Cancer and Liver Fibrosis

Tokyo, Japan, May 21, 2026: United Immunity, Co., Ltd., a biotechnology company developing its proprietary Myeloid Targeting Platform™ for therapeutic in vivo engineering of disease-associated macrophages and dendritic cells, today announced the acquisition of multiple assets from Carisma Therapeutics Inc..

United Immunity plans to leverage these innovative assets in combination with its PEG-free, pullulan-coated lipid nanoparticle (P-LNP) delivery system to generate in vivo CAR-M and other genetically engineered macrophages. This integrated approach aims to advance next-generation therapies for solid tumors and fibrosis diseases.

“Both assets has novel technologies to boost the efficacy of in vivo engineered anti-tumor or anti-fibrotic macrophages,” said Masato Kishida, Chief Executive Officer of United Immunity. “Our in vivo CAR-M therapy boosted by these proprietary assets represent a promising therapeutic approach for patients with solid tumors. In addition, United Immunity’s active targeting in vivo CAR-M strategy may provide an improved safety profile by reducing the risk of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), which are frequently associated with CAR-T cell therapies.”

About United Immunity, Co., Ltd.

Unite the power of immunity and nanoparticle, change the future of patients

United Immunity is a clinical stage biotechnology company developing a novel Myeloid Targeting Platform™ designed to deliver therapeutic payloads directly to disease-associated macrophages and dendritic cells. Its platform combines pullulan nanoparticles (PNPs) and PEG-free, pullulan-coated lipid nanoparticles (P-LNPs) to enable targeted delivery of a wide range of therapeutics, including small molecules, nucleic acids, peptides, and proteins. This approach aims to address major unmet needs across cancer, fibrosis, infectious, autoimmune, and inflammatory diseases.

The company’s lead program, UI-102, leverages its PNP technology to deliver a TLR7/8 small-molecule agonist to tumor-associated macrophages, with the goal of converting immunologically “cold” tumors into “hot,” immune-sensitive ones. In parallel, United Immunity is advancing its P-LNP platform to enable the in vivo generation of CAR-

macrophages, opening new therapeutic possibilities for cancer, fibrosis, and autoimmune diseases.

For more information, please visit www.unitedimmunity.co.jp/eng/
www.linkedin.com/company/unitedimmunitycoltd

Contact
Masato Kishida, CEO
e-mail: info@unitedimmunity.co.jp

ユナイテッド・イミュニティ、**Carisma Therapeutics** からの技術資産買収を完了

マクロファージや樹状細胞の選択的な活性化を通じて、がんや線維症の患者さんに画期的な治療体験を届けることを目指すユナイテッド・イミュニティ株式会社（本社：東京都中央区、代表取締役社長：岸田将人、以下 UI）は、**Carisma Therapeutics** からの技術資産の買収を終えたことをお知らせします。

「買収した技術資産はいずれも、生体内のマクロファージの改変によって抗腫瘍性または抗線維化の有効性を高める画期的な技術やプログラムであり、マクロファージへ遺伝子を能動的かつ選択的に送達可能な当社の P-LNP 技術への親和性が高いものとなります」と、United Immunity の岸田将人は述べます。
「Carisma 独自の資産によって強化された当社の in vivo CAR-M プログラムは、固形

がん患者に対して既存療法にない利点をもたらす可能性があります。さらに、当社の in vivo CAR-M プログラムは、CAR-T 細胞療法で頻繁に見られるサイトカイン放出症候群（CRS）および免疫エフェクター細胞関連神経毒性症候群（ICANS）のリスクを低減することで、安全性プロファイルの改善につながる可能性があります。」

Carisma Therapeutics は米国におけるマクロファージ領域の有力企業で、CAR-M 細胞療法で Ph1 臨床試験を実施した経験があります。当社は Carisma 社の資産を継承することで、自然免疫領域の世界的な創薬企業への階段を、一歩駆け上がることとなります。

■ ユナイテッド・イミュニティ株式会社 概要

所在地：東京都中央区日本橋室町一丁目１２番３号

代表者：代表取締役社長 岸田 将人（きしだ まさと）

URL: https://unitedimmunity.co.jp/